<?xml version="1.0" encoding="UTF-8"?>
<p>Despite the availability of potent antivirals and vaccination against the hepatitis B virus (HBV), chronic HBV infection remains a significant socioeconomic burden. The global prevalence of chronic HBV in 2016 was close to 3.9%, which equates to approximately 292 million HBsAg-positive individuals, making it one of the most common human pathogens, and there is large regional variation[
 <xref rid="pone.0227532.ref001" ref-type="bibr">1</xref>]. In addition to its effects on the liver, patients with HBV have extrahepatic manifestations of renal disease. In a single-center retrospective trial, Zhang et al[
 <xref rid="pone.0227532.ref002" ref-type="bibr">2</xref>] reported that 3% (n = 352) of a total of 11,618 kidney biopsies performed from 1987 to 2012 in Beijing, China, were HBV-GN positive.
</p>
